27
A PHASE 1/2 OPEN LABEL EXTENSION STUDY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA
a Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, Brazil
b King's College Hospital, London, United Kingdom
c University of Texas Medical Branch, Galveston, United States
d Wake Forest University NC Baptist Medical Center, Winston-Salem, United States
e Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
f Icahn School of Medicine at Mt. Sinai, New York, United States
Read
2196
Timeswas read the article
1070
Total PDF
1126
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 April | 28 | 14 | 42 |
| 2024 March | 39 | 27 | 66 |
| 2024 February | 35 | 21 | 56 |
| 2024 January | 24 | 20 | 44 |
| 2023 December | 33 | 31 | 64 |
| 2023 November | 44 | 28 | 72 |
| 2023 October | 24 | 27 | 51 |
| 2023 September | 50 | 39 | 89 |
| 2023 August | 29 | 11 | 40 |
| 2023 July | 38 | 15 | 53 |
| 2023 June | 28 | 23 | 51 |
| 2023 May | 29 | 15 | 44 |
| 2023 April | 25 | 12 | 37 |
| 2023 March | 34 | 20 | 54 |
| 2023 February | 30 | 23 | 53 |
| 2023 January | 18 | 10 | 28 |
| 2022 December | 32 | 18 | 50 |
| 2022 November | 32 | 23 | 55 |
| 2022 October | 41 | 23 | 64 |
| 2022 September | 43 | 26 | 69 |
| 2022 August | 22 | 35 | 57 |
| 2022 July | 26 | 30 | 56 |
| 2022 June | 17 | 24 | 41 |
| 2022 May | 22 | 27 | 49 |
| 2022 April | 36 | 48 | 84 |
| 2022 March | 20 | 24 | 44 |
| 2022 February | 17 | 30 | 47 |
| 2022 January | 21 | 29 | 50 |
| 2021 December | 14 | 18 | 32 |
| 2021 November | 19 | 32 | 51 |
| 2021 October | 41 | 43 | 84 |
| 2021 September | 20 | 27 | 47 |
| 2021 August | 23 | 41 | 64 |
| 2021 July | 23 | 25 | 48 |
| 2021 June | 17 | 19 | 36 |
| 2021 May | 15 | 52 | 67 |
| 2021 April | 32 | 39 | 71 |
| 2021 March | 17 | 32 | 49 |
| 2021 February | 15 | 16 | 31 |
| 2021 January | 11 | 17 | 28 |
| 2020 December | 14 | 15 | 29 |
| 2020 November | 28 | 21 | 49 |
Show all
